Research & Development
Heritage Pharma Labs Inc reports addition of 23 US FDA approved ANDAs
7 February 2019 -

Pharmaceutical company Heritage Pharma Labs Inc revealed on Wednesday the completion of the acquisition of portfolio of 23 abbreviated new drug applications (ANDAs), including 17 US Food and Drug Administration (FDA) approved products families.

In the Q2 2019, the company intends to immediately launch all of these products into the US market under its label and through its affiliate, Heritage Pharmaceuticals Inc.

According to the company, these newly acquired products have been previously manufactured under a supply agreement with its parent company, Emcure Pharmaceuticals Ltd and a third party

The financial terms of the acquisition were not disclosed by the company.